Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Status:
Completed
Trial end date:
2014-09-15
Target enrollment:
Participant gender:
Summary
Protocol 603 is enrolling subjects with moderate-to-severe Crohn's disease who are intolerant
to, or have previously failed therapy with, at least one steroid and at least one
immunosuppressant and a biologic monoclonal anti-body to tumor necrosis factor alpha. The
protocol investigates the safety and efficacy of using PROCHYMAL® adult human stem cells to
induce remission. PROCHYMAL is delivered through a vein in the arm four times over two weeks,
for approximately an hour each time.